Michigan is currently home to 2240 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Ann Arbor, Detroit, Grand Rapids and Kalamazoo. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
PTNS for Female Patients Suffering From Multiple Sclerosis
Recruiting
This is a pilot, single blind, randomized, sham-controlled trial to assess the benefit of PTNS in treating OAB symptoms in MS patients. The data generated by this study would provide support for a future multi-institutional, randomized prospective trial.
Gender:
Female
Ages:
18 years and above
Trial Updated:
02/06/2023
Locations: Beaumont Hospital - Royal Oak, Royal Oak, Michigan
Conditions: Multiple Sclerosis, Overactive Bladder
Growth Hormone Replacement Therapy for Retried Professional Football Players
Recruiting
This is a randomized, double-blind, placebo-controlled, parallel-group trial with an open-label extension to evaluate the efficacy of growth hormone (GH) on cognitive functions of retired professional football players with growth hormone deficiency (GHD).
Gender:
Male
Ages:
Between 18 years and 76 years
Trial Updated:
02/06/2023
Locations: Center for Neurolgoical Studies (CNS), Dearborn, Michigan
Conditions: TBI (Traumatic Brain Injury), Concussion, Brain, Sport Injury, Anterior Pituitary Hyposecretion Syndrome, Hypopituitarism, Growth Hormone Deficiency
Apixaban for the Acute Treatment of Venous Thromboembolism in Children
Recruiting
To assess the safety and descriptive efficacy of apixaban in pediatric subjects requiring anticoagulation for the treatment of a VTE.
Gender:
All
Ages:
Between 0 days and 17 years
Trial Updated:
02/06/2023
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Venous Thromboembolism
Improving Communication and Healthcare Outcomes for Patients With Communication Disabilities
Recruiting
In the United States, 14% of all adults report a speech, language, voice, and/or hearing disability (collectively known as communication disabilities, CD). Patients with CD, experience inequities in receipt of and access to high-quality healthcare services, including primary care. Poor patient-provider communication is a significant contributor to these disparities. When healthcare providers use evidence-based communication strategies, patients with CD have improved communication outcomes and sa... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/01/2023
Locations: Michigan Medicine, Ann Arbor, Michigan
Conditions: Communication Disabilities
A Performance Evaluation Study of Arquer's MCM5 Elisa Test (ADXBLADDER) to Aid in the Monitoring of Recurrence in Non-Muscle Invasive Bladder Cancer
Recruiting
The objective of this prospective, multi-centre study is to evaluate the performance of ADXBLADDER, a urine MCM5 ELISA test, as an aid in the detection of bladder cancer recurrence. Patients undergoing cystoscopic surveillance in non-muscle invasive bladder cancer (NMIBC) follow-up will be recruited and asked to provide a urine sample to be tested with ADXBLADDER. To assess the diagnostic accuracy of the test, the MCM5 results will be compared with the gold standard cystoscopy and pathology of r... Read More
Gender:
All
Ages:
22 years and above
Trial Updated:
01/30/2023
Locations: Michigan Institute of Urology, Troy, Michigan
Conditions: Bladder Cancer
A Study of ZN-c3 in Participants With Solid Tumors
Recruiting
This is a Phase 1 open-label, multicenter study of ZN-c3 monotherapy which consists of Dose Escalation, a Food Effect Cohort, and Dose Expansion.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/30/2023
Locations: Site 0101, Detroit, Michigan
Conditions: Solid Tumor
Treatment of Adenocarcinoma of the Rectum With Transanal Local Excision for Complete Responders
Recruiting
The current standard of care for rectal cancer has diminished local recurrence and enhanced survival. Quality of life, however, remains poor for many patients and the probability of distant recurrence is high. In this study, we will attempt to reduce the distant recurrence rate and improve quality of life by making changes in the timing and administration of chemotherapy and radiation and doing less invasive rectal surgery when indicated.
Gender:
All
Ages:
Between 18 years and 95 years
Trial Updated:
01/30/2023
Locations: Ascension St. John Hospital, Detroit, Michigan
Conditions: Rectal Cancer
Improving the Part C Early Intervention Service Delivery System for Children With ASD
Recruiting
Despite strong consensus that early, specialized intervention for children with Autism Spectrum Disorder (ASD) can have a dramatic impact on outcomes, the public health system's capacity to provide such services is severely challenged by the rapid rise in ASD prevalence. The goal of this research project is to increase timely and equitable access to ASD-specialized early intervention during the critical first three years of life by capitalizing on the existing infrastructure of the Part C Early... Read More
Gender:
All
Ages:
Between 16 months and 30 months
Trial Updated:
01/27/2023
Locations: Michigan State University, East Lansing, Michigan
Conditions: Autism Spectrum Disorder
Proof of Concept Study to Eval MetriDx Lab-developed Test to Identify Endometriosis-specific Bio Markers
Recruiting
This study is testing a way to diagnose endometriosis using a uterine tissue biopsy (similar to a pap smear) as opposed to undergoing laparoscopy surgery. The tissue is sent to lab for cellular analysis with a proprietary AI (artificial intelligence) technology.
Gender:
Female
Ages:
Between 18 years and 50 years
Trial Updated:
01/24/2023
Locations: Valley OB-GYN Clinic, PC, Saginaw, Michigan
Conditions: Endometriosis, Diagnosis
Efficacy of EsoGuard Assay on Esophageal Surface Cells Collected With EsoCheck vs EGD for the Diagnosis of BE or EAC
Recruiting
The study will assess the performance of the combined system, i.e., the use of the EsoGuard assay (lab developed test) on cells collected using the EsoCheck (501k cleared device) to detect Barrett's Esophagus (BE), with or without dysplasia, and esophageal adenocarcinoma (EAC) as compared to Esophagogastroduodenoscopy (EGD) plus biopsies in both confirmed cases of BE/EAC and in controls (subjects without a prior diagnosis but undergoing screening for BE/EAC)
Gender:
Male
Ages:
50 years and above
Trial Updated:
01/23/2023
Locations: Lucid Investigative Site, Ann Arbor, Michigan
Conditions: Barrett Esophagus, Esophageal Adenocarcinoma, Barretts Esophagus With Dysplasia, Barrett's Esophagus Without Dysplasia
Low FODMAP Plus PEG 3350 for the Treatment of Patients With Irritable Bowel Syndrome-Constipation
Recruiting
Consecutive patients with Irritable Bowel Syndrome with Constipation (IBS-C) will be recruited from the outpatient clinics of the University of Michigan Health System. Eligible patients will be asked to participate in a study that will test the efficacy the PEG 3350 + a diet low in fermentable oligo, di, monosaccharides, and polyols (FODMAP) vs. PEG 3350 plus sham diet. Blinding dietary advice trials is challenging and therefore the sham diet was based on the criteria set forth by Staudacher et... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
01/18/2023
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Irritable Bowel Syndrome Characterized by Constipation
Study of the Safety and Efficacy of STI-6129 in Patients With Relapsed or Refractory Systemic AL Amyloidosis
Recruiting
The STI-6129-001 study is a three-stage, multicenter, open-label, dose-finding, phase 1b/2a trial. It is designed primarily to identify the recommended phase 2 dose (RP2D) of STI-6129 by assessing the safety, preliminary efficacy and pharmacokinetics of this anti-CD38-Duostatin 5.2 antibody-drug conjugate (ADC) for the treatment of relapsed or refractory systemic AL amyloidosis. The patients that will be treated with STI-6129 in this trial are relapsed or refractory systemic AL amyloidosis pati... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
01/12/2023
Locations: Barbara Ann Karmanos Cancer Institute Wertz Clinic, Detroit, Michigan
Conditions: Light Chain (AL) Amyloidosis